Clinical Trial Update: This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease. [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, feasibility and preliminary efficacy of NouvNeu001 (human dopaminergic progenitor cell injections) for Parkinson'…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• NouvNeu001

Snippet

Sponsor: iRegene Therapeutics Co., Ltd. | Conditions: Parkinson Disease | Phase 1 | Status: RECRUITING